Go Pro
NASDAQ:IDXX

IDEXX Laboratories (IDXX) Stock Price, News & Analysis

IDEXX Laboratories logo
$506.53 -8.62 (-1.67%)
Closing price 09/10/2026 04:00 PM Eastern
Extended Trading
$507.00 +0.47 (+0.09%)
As of 09/10/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About IDEXX Laboratories Stock (NASDAQ:IDXX)

Advanced

Key Stats

Today's Range
$504.77
$514.30
50-Day Range
$506.53
$595.76
52-Week Range
$504.77
$769.98
Volume
422,339 shs
Average Volume
484,379 shs
Market Capitalization
$39.90 billion
P/E Ratio
35.62
Dividend Yield
N/A
Price Target
$747.00
Consensus Rating
Moderate Buy

Company Overview

IDEXX Laboratories, Inc. develops and provides diagnostic, information technology and veterinary practice-management products and services. The company primarily serves the companion animal, livestock and poultry, and water testing markets, helping customers detect, monitor and manage disease.

Its companion animal business includes in-house laboratory analyzers and consumables, reference laboratory services, diagnostic tests, veterinary software, digital imaging and related practice-management solutions. IDEXX also provides diagnostic products and services for livestock and poultry, as well as microbiology testing systems and services used to assess the safety and quality of water.

Founded in 1983 and headquartered in Westbrook, Maine, IDEXX serves veterinary practices, commercial laboratories, public health organizations and other customers internationally. The company operates through a global network of offices, laboratories and distribution capabilities. Jay Mazelsky has served as IDEXX’s president and chief executive officer since 2022.

AI Generated. May Contain Errors.

IDEXX Laboratories Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
83rd Percentile Overall Score

IDXX MarketRank™: 

IDEXX Laboratories scored higher than 83% of companies evaluated by MarketBeat, and ranked 73rd out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    IDEXX Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 6 buy ratings, 4 hold ratings, and no sell ratings.

  • Upside Potential

    IDEXX Laboratories has a consensus price target of $747.00, representing about 47.5% upside from its current price of $506.53.

  • Amount of Analyst Coverage

    IDEXX Laboratories has only been the subject of 4 research reports in the past 90 days.

  • Read more about IDEXX Laboratories' stock forecast and price target.
  • Earnings Growth

    Earnings for IDEXX Laboratories are expected to grow by 12.22% in the coming year, from $14.81 to $16.62 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of IDEXX Laboratories is 35.62, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.73.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of IDEXX Laboratories is 35.62, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 272.81.

  • Price to Earnings Growth Ratio

    IDEXX Laboratories has a PEG Ratio of 2.75. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    IDEXX Laboratories has a P/B Ratio of 25.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about IDEXX Laboratories' valuation and earnings.
  • Percentage of Shares Shorted

    2.68% of the float of IDEXX Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    IDEXX Laboratories has a short interest ratio ("days to cover") of 4.35.
  • Change versus previous month

    Short interest in IDEXX Laboratories has recently increased by 7.98%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    IDEXX Laboratories does not currently pay a dividend.

  • Dividend Growth

    IDEXX Laboratories does not have a long track record of dividend growth.

  • News Sentiment

    IDEXX Laboratories has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 18 news articles for IDEXX Laboratories this week, compared to 5 articles on an average week.
  • Search Interest

    Only 2 people have searched for IDXX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added IDEXX Laboratories to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, IDEXX Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,172,172.00 in company stock.

  • Percentage Held by Insiders

    0.79% of the stock of IDEXX Laboratories is held by insiders.

  • Percentage Held by Institutions

    87.84% of the stock of IDEXX Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about IDEXX Laboratories' insider trading history.
Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IDXX Stock News Headlines

Is IDEXX Laboratories Stock Underperforming the Dow?
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
IDEXX Laboratories (NASDAQ:IDXX) Director Sells $1,172,172.24 in Stock
IDEXX Laboratories IDXX Falls to a Fresh 52-Week Low at $520.21
See More Headlines

IDXX Stock Analysis - Frequently Asked Questions

IDEXX Laboratories' stock was trading at $676.53 on January 1st, 2026. Since then, IDXX shares have decreased by 25.1% and is now trading at $506.53.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) posted its quarterly earnings data on Tuesday, August, 4th. The company reported $4.27 EPS for the quarter, topping the consensus estimate of $3.94 by $0.33. The company's revenue for the quarter was up 9.7% compared to the same quarter last year.
Read the conference call transcript
.

Top institutional investors of IDEXX Laboratories include California State Teachers Retirement System (78.18%), Bank of New York Mellon Corp (1.51%), Fundsmith LLP (1.29%) and UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (1.16%). Insiders that own company stock include Jonathan Jay Mazelsky, Brian P Mckeon, Nimrata Hunt, Michael G Erickson, James F Polewaczyk, George Fennell, Michael Lane, Sharon E Underberg, Sophie V Vandebroek, M Anne Szostak and Bruce L Claflin.
View institutional ownership trends
.

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that IDEXX Laboratories investors own include Tesla (TSLA), Broadcom (AVGO), Applied Materials (AMAT), HubSpot (HUBS), ASML (ASML), CrowdStrike (CRWD) and Cadence Design Systems (CDNS).

Company Calendar

Last Earnings
8/04/2026
Today
9/10/2026
Morgan Stanley 24th Annual Global Healthcare Conference
9/14/2026
Barclays 24th Annual Global Financial Services Conference
9/14/2026
Next Earnings (Estimated)
11/02/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NASDAQ:IDXX
CIK
874716
Employees
11,000
Year Founded
1983

Price Target and Rating

High Price Target
$830.00
Low Price Target
$670.00
Potential Upside/Downside
+47.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
$14.22
Trailing P/E Ratio
35.62
Forward P/E Ratio
34.20
P/E Growth
2.75
Net Income
$1.06 billion
Net Margins
25.03%
Pretax Margin
31.28%
Return on Equity
71.96%
Return on Assets
33.60%

Debt

Debt-to-Equity Ratio
0.19
Current Ratio
1.17
Quick Ratio
0.87

Sales & Book Value

Annual Sales
$4.30 billion
Price / Sales
9.27
Cash Flow
$14.83 per share
Price / Cash Flow
34.15
Book Value
$20.10 per share
Price / Book
25.20

Miscellaneous

Outstanding Shares
78,780,000
Free Float
78,159,000
Market Cap
$39.90 billion
Optionable
Optionable
Beta
1.54

Social Links

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NASDAQ:IDXX) was last updated on 9/11/2026 by MarketBeat.com Staff.
From Our Partners